Lumasiran - ≥95% , CAS No.1834610-13-7

CAS: 1834610-13-7 Cat. No.: L647658 Molecular Weight: 16339.00 (AS: 7631.0 +SS: 8708.0)

GRADE & PURITY ≥95%

Storage

Store at -20°C,Argon charged,Desiccated

Shipped In

Ice chest + Ice pads

Overview

Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase. By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the toxic metabolite that is directly associated with the clinical manifestations of Primary hyperoxaluria type 1 (PH1).

In Vitro

Lumasiran reduced urinary oxalate excretion, the cause of progressive kidney failure in PH1. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Lumasiran is a subcutaneously administered, liver-directed RNA interference (RNAi) therapeutic agent. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Form:Solid

Specifications

Specifications & Purity

≥95%

Biochemical and Physiological Mechanisms

Lumasiran (ALN-G01), a siRNA product, reduces hepatic oxalate production by targeting glycolate oxidase . By silencing the gene encoding glycolate oxidase, Lumasiran depletes glycolate oxidase and thereby inhibits the synthesis of oxalate, which is the to

Storage

Store at -20°C, Argon charged, Desiccated

Shipped In

Ice chest + Ice pads

This product requires cold chain shipping. Ground and other economy services are not available.

Purity

≥95%

Names and Identifiers

• Canonical Smiles: [Lumasiran]
• Molecular Weight: 16339.00 (AS: 7631.0 +SS: 8708.0)

Chemical and Physical Properties

• Solubility: H2O : 100 mg/mL (Need ultrasonic)